US 11,987,802 B2
Oncolytic virus vector and application thereof
Ziying Gong, Shanghai (CN); Daoyun Zhang, Shanghai (CN); Yonghua Sun, Shanghai (CN); Yi Wang, Shanghai (CN); Nan Shi, Shanghai (CN); Jun Zhu, Shanghai (CN); and Miao Ding, Shanghai (CN)
Assigned to SHANGHAI YUNYING BIOPHARMACEUTICAL TECHNOLOGY CO., LTD., Shanghai (CN)
Filed by SHANGHAI YUNYING BIOPHARMACEUTICAL TECHNOLOGY CO., LTD., Shanghai (CN)
Filed on Jul. 11, 2023, as Appl. No. 18/349,983.
Application 18/349,983 is a continuation of application No. PCT/CN2021/098139, filed on Jun. 3, 2021.
Prior Publication US 2024/0002884 A1, Jan. 4, 2024
Int. Cl. C12N 7/01 (2006.01); C07K 14/035 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)
CPC C12N 15/86 (2013.01) [C07K 14/035 (2013.01); C07K 14/70503 (2013.01); C07K 14/70532 (2013.01); C07K 16/2809 (2013.01); C12N 2710/16043 (2013.01)] 9 Claims
 
1. An oncolytic virus containing a recombinant nucleic acid, wherein the recombinant nucleic acid comprises:
(i) a first nucleic acid fragment encoding a soluble PD-1 molecule;
(ii) a second nucleic acid fragment encoding a CD86 molecule;
(iii) a third nucleic acid fragment encoding an antibody to a CD3 molecule; and
(iv) a fourth nucleic acid fragment encoding a US11 protein, wherein:
the oncolytic virus is an HSV-1 virus, and
the recombinant nucleic acid has a sequence of SEQ ID NO: 5.